Engineered immune cells show promise against tough blood cancer
NCT ID NCT03455972
First seen Mar 29, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This study tests a treatment that uses a patient's own immune cells, modified to target two proteins (CD19 and BCMA) on myeloma cells, after a stem cell transplant. The goal is to see if this approach is safe and can control high-risk multiple myeloma. About 43 participants will be enrolled, and researchers will monitor side effects, how long the treatment works, and whether the cancer stays away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AND EFFICACY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.